Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women

NCT04098900 — Completed, 309 participants, Visby Medical

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04098900
StatusCompleted
Study typeObservational
Enrollment309 (Actual)
SponsorVisby Medical (Industry)
ConditionsChlamydial Infection, Gonococcal Infection, Trichomoniasis
InterventionsClick Sexual Health Test (Diagnostic test)
Datesstart 2019-09-16, primary completion 2019-12-03, completion 2019-12-03, first posted 2019-09-23, last updated 2020-02-17
Locations5 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Chlamydial Infection All trials for Gonococcal Infection All trials of Click Sexual Health Test

-Summary

This study is a multi-center study with a minimum of three CLIA-waived intended operator sites in the United States in which prospectively self-collected vaginal specimens obtained from subjects who are symptomatic or asymptomatic for CT, NG, or TV will be evaluated with the Click Sexual Health Test in a Clinical Laboratory Improvement Amendments (CLIA) waived setting. Subjects interested in participating in this study will be assessed for eligibility and asked to give informed consent and assent, if applicable, by the Investigational Review Board (IRB). Only those subjects who meet the inclusion and exclusion criteria may be enrolled in the study.

Expand all sections  ·  Collapse all

+Arms and interventions

  • Click Sexual Health Test (Diagnostic test): The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.

+Outcome measures

Primary outcomes

  • The percent sensitivity and specificity of the Click Device for detection of CT in self-collected vaginal specimens as compared to Patient Infected Status (PIS) using vaginal specimens collected by a qualified Health Care Provider (HCP) [up to 6 months]
  • The percent sensitivity and specificity of the Click Device for detection of NG in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP [up to 6 months]
  • The percent sensitivity and specificity of the Click Device for detection of TV in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP [up to 6 months]

Secondary outcomes

  • Usability will be measured by 5-point Likert scale responses, yes/no questions, and open text questions from study operators. [up to 6 months]: Questions are around three domains of interest: i) instructions, ii) operations, and iii) visual interpretation for the Click device for detection of CT, NG, and TV with patient self-collected specimens. The 5-point Likert scale will measure responses to questions in the form of: (1) Strongly Disagree, (2) Disagree, (3) Neutral, (4) Agree, and (5) Strongly Agree

+Eligibility

Sex: Female, ages: 14 Years to 99 Years, accepts healthy volunteers

Inclusion Criteria:

1. Willing and able to give voluntary written informed consent and assent form (or the parental/legal guardian will provide parental permission) before any study-related procedure is performed.
2. Female at birth. (Pregnant and breastfeeding women are eligible).
3. Age greater than or equal to 14 years at the time of enrollment
4. Able to read and understand the procedural information provided for the study.
5. Able and willing to follow all study procedures, including performing self-collection of one vaginal swab and permitting a HCP to collect three additional vaginal swabs.

Exclusion Criteria:

1. Have a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgement, could jeopardize the subjects's safety, or could interfere with study procedures.
2. Enrollment in the DMID 18-0024 and this study previously.
3. Use of antiperspirants and deodorants or the following vaginal products: douches, washes, lubricants, vaginal wipes, vaginal moisturizers, or feminine hygiene spray in the genital area, within 48 hours prior to enrollment.

+Locations (5)

FacilityCityCountryStatus
Therafirst Medical CenterFort Lauderdale, FloridaUnited States
Planned Parenthood North Central StatesSaint Paul, MinnesotaUnited States
Planned Parenthood of the St. Louis Region and Southwest MissouriSt Louis, MissouriUnited States
Lawrence OB/GYN Clinical Research, LLCLawrenceville, New JerseyUnited States
Planned Parenthood Gulf CoastHouston, TexasUnited States